Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
A precision, computer-vision measurement system for the early diagnosis of schizophrenia (Gazelab)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Spain
Call: Clinical research for the validation of biomarkers and/or diagnostic medical devices (H2020-SMEINST-1-2015, 2015)
Start date: 2015-05-01
End date: 2015-10-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Strabismus, the disorder in which the eyes do not line up in the same direction, affects around 10.5 million Europeans. Around 30% of strabismus surgeries need to be repeated due to inaccurate ocular measurements. At any point in time, about 10% of the adult population will report having some type of mental or behavioral disorder, such as schizophrenia. These two seemingly unrelated pathologies have one thing in common: they can be detected using ocular biomarkers. The goal of this project is to validate ocular biomarkers for a range of pathologies, including ophthalmological, neurological, mental, and endocrinological disorders. The clinical validations will be conducted using GazeLab, a computer vision-based system that accurately measures ocular motility and pupillary dynamics. Our innovative all-in-one solution can be deployed as a point-of-care diagnostic tool, leading to quicker and more effective treatments for a variety of disorders. Strabismus patients are the first beneficiaries of our technology and are currently driving demand for GazeLab within the ophthalmological sector. As we validate more biomarkers for ocular pathologies we will add value to our product for ophthalmologists. Mental health professionals overwhelmingly diagnose subjectively, and can miss physiological symptoms that ocular biomarkers can detect. The goal of this SME Instrument phase 1 project is to determine if GazeLab represents a scalable, repeatable business model to help diagnose a variety of pathologies. If this is the case, we will proceed to request funding through phase 2. In phase 2 we aim to conduct large-scale validations necessary for GazeLab to be approved for the defined applications in a clinical setting. Our target markets include ophthalmologists, neuro-ophthalmologists, neurologists and psychiatrists. Our ultimate goal is to position GazeLab as the industry standard for precision ocular motility measurement and pupillography throughout a range of clinical specialties

Keywords: biomechanical ocular biomarkers,ophthalmology,neuro ophthalmology,computer vision,mental,health,ocular motility,pupillary dynamics,strabismus,nystagmus
Effective Clinical reasoning in Virtual Patients (VirtualPatients)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,United States
Call: Marie Skłodowska-Curie Individual Fellowships (IF-GF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-07-01
End date: 2017-12-31
Duration (months): 30.0
Total project cost (EUR): 199828.2
EU funding (EUR): 199828.2
Participants: 2
Project status: CLOSED

The European Commission estimates in the report "Patient Safety and Quality of Care" (2014)1 that each year 8 - 12% of hospitalized patients suffer from adverse events, including errors in diagnosis. One reason for the occurrence of such errors is a lack of clinical reasoning skills, a core competency that medical students have to learn during their studies (Norman 2005, Scott 2009). Clinical reasoning is often taught in face-to-face courses such as bedside-teaching, problem-based tutorials or during internships. Since the early nineties virtual patients (VPs) became more and more important in medical education to teach clinical reasoning skills (Cook 2009). The knowledge gap this project addresses was raised by Cook et al. (2009, 2010) and, until know, remains unaddressed. He concluded that there is no evidence how VP design variations influence clinical reasoning acquisition and that it is not fully understood how VPs teach clinical reasoning and how this process could be improved. Therefore, in this project research will be undertaken to develop and assess an effective clinical reasoning tool to be embedded into VPs, and create guidelines on how to implement the tool based on the outcomes of an interdisciplinary grounded theory approach. The success of the project builds on the applicant's strong expertise in creating, integrating, and researching VPs, as well as on her interdisciplinary background in medicine, medical education research, and computer science, which enables her to manage all aspects of the project. The project will have a major impact on the applicant's career development, enabling her to become an independent researcher and ultimately establish her own research group within the field of virtual patients. Such a detailed elaboration of clinical reasoning in VPs will improve students' diagnostic skills potentially leading to a reduction of diagnostic errors, avoiding unnecessary treatment and pain for patients and reducing healthcare costs.

Keywords: medical education,virtual patients,clinical reasoning skills,e learning,teaching
Pyrolytic Hierarchical Organic Electrodes for sustaiNable Electrochemical Energy Systems (PHOENEEX)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Systems and communication engineering
Panel description: Electrical, electronic, communication, optical and systems engineering
Countries involved: Denmark
Call: ERC Consolidator Grant (ERC-2017-COG, 2017)
Start date: 2018-05-01
End date: 2023-10-31
Duration (months): 66.0
Total project cost (EUR): 2745500.0
EU funding (EUR): 2745500.0
Participants: 1
Project status: SIGNED

The demand for compact energy systems for portable devices such as wearable sensors or mobile phones is increasing. Electrochemical systems are promising candidates for sustainable energy conversion and storage on miniaturised platforms. A recent approach to harvest green energy is biophotovoltaic systems (BPVs), where photosynthetic microorganisms are used to transform light into electrical energy. However, BPVs still provide a relatively low efficiency and are yet unable to deliver the high peak power required for sensor operation or wireless signal transmission in portable systems. In PHOENEEX, I will address these limitations by i) improving the efficiency of BPVs and ii) combining the BPVs with microsupercapacitors (µSCs) which can temporarily store the harvested electrical energy and provide a higher peak power output upon request. More specifically, I will develop highly optimised 3D carbon microelectrodes (3DCMEs) to enhance electron harvesting from cyanobacteria in BPVs and for increased energy density in µSCs. Finally, the improved BPVs and the optimised µSCs will be integrated on the BioCapacitor Microchip - a compact sustainable energy platform for portable systems. The fabrication of 3DCMEs with highly tailored material properties, large surface area and hierarchical architecture is achieved by pyrolysis of polymer templates in an inert atmosphere. The fundamental hypothesis of PHOENEEX is that the combination of novel precursor materials, new methods for 3D polymer microfabrication and optimised pyrolysis processes will allow for fabrication of 3DCMEs with highly tailored material properties, large surface area and hierarchical architecture impossible to obtain with any other method.
Micro Market Experience (MiMEX)

Framework: Horizon 2020 — Industrial Leadership
Action type: Innovation actions
Countries involved: Italy,Italy,Spain,Türkiye
Call: Fast Track to Innovation (FTI) (H2020-EIC-FTI-2018-2020, 2020)
Start date: 2020-12-01
End date: 2022-11-30
Duration (months): 24.0
Total project cost (EUR): 2881125.0
EU funding (EUR): 2194912.5
Participants: 5
Project status: SIGNED

The retail world is going through a period of strong evolution, accelerated by the ongoing COVID-19 pandemic. E-commerce has been shown to be a pillar of society and through necessity it outperformed physical shop retail in many product sectors, e.g. electronics, books. To cope with new social distancing measures being enforced by nearly all countries, in the near future traditional bricks-and-mortar retailers must introduce innovations that can help them to maintain their profit margins and support customers’ choice, access and most importantly their employees’ safety. Shoppers are demanding reduced waiting times, the possibility of buying a greater variety of products when they want them, i.e. 24-hour opening hours, and to feel safe when shopping. The solution we have developed in MiMEX, using intelligent shelves, and connected smart spaces targets these problems and opportunities. We propose to automate social distancing checks and adhere to regional safety protocols (such as wearing gloves and masks). We will exploit deep-learning algorithms and low-cost sensors to answer product choice and availability needs. We will create a complete hardware & software micro-market solution that can monitor shoppers’ safety and simultaneously track products/goods collected by customers in real-time inside a store, facilitating smart and safe checkout with bespoke payment systems. A complete monitoring system will make it possible to offer high-value services such as exhausted product alarms, attempted thefts or display-shelf tidying requests to retailers.

Keywords: micro market,object detection,people tracking system
Intelligent Innovative Smart Maintenance of Assets by integRated Technologies 2 (IN2SMART2)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Theme: Public-private partnerships
Destination: European rail initiative
Action type: Innovation actions
Partnership: Shift2Rail (Art-187)
Countries involved: Austria,Germany,Germany,Germany,Spain,Spain,Spain,Italy,Italy,Germany,Austria,Italy,Sweden,Switzerland,Sweden,Sweden,France,France,Netherlands,United Kingdom,United Kingdom,United Kingdom,United Kingdom,Portugal,United Kingdom
Call: Intelligent asset management finalisation (H2020-S2RJU-CFM-2019, 2019)
Start date: 2019-12-01
End date: 2023-09-30
Duration (months): 46.0
Total project cost (EUR): 13124244.41
EU funding (EUR): 10241024.48
Participants: 29
Project status: SIGNED

This project represents the continuation of the work initially carried out through the In2Rail “lighthouse project” and mainly through the work of the IN2SMART project. These projects form together part of the framework of research and innovation that will deliver the vision and strategy of Innovation Programme 3. There is a demand for a step change in asset management to be delivered through innovative technologies, new economic possibilities, and enhanced legislative standards in the rail sector. As set-out in the S2R Multi-Annual Action Plan, the Intelligent Asset Maintenance Pillar is a driver to deliver innovative asset management, meeting the best practice set out in ISO55000 in the railway sector. The Intelligent Asset Management Pillar is an accelerator creating new and optimised strategies, frameworks, processes and methodologies, tools, products and systems for the implementation of a step change in risk based, prescriptive and holistic asset management in the rail sector. A series of vertical TRL 6/7 demonstrators, covering all Asset Maintenance Pillar aspects, such as data collection (TD3.7), data analytics and interfaces (TD3.6), decision support and lean working methods (TD3.8), will be defined and demonstrated in relevant environment, spreading the innovation results throughout European main railway and metro/tram lines. The demonstrator’s scope of work in the majority of cases will be on asset management optimization at tactical and operational levels, with a few examples of strategical ones. Innovation potential of aspects such as the utilization of a digital twin and robotic automated platforms will also be investigated in some demonstrators. Coherence and uniformity will be guaranteed through a common system architecture and Conceptual Data Model usage, common validation approach and final integrated demonstrator, enabling a common monitoring solution collecting heterogeneous inputs from various vertical demonstrators.

Keywords: intelligent asset management system,decision support system
Enhancing the innovation management capacity of SMEs through the Enterprise Europe Network in Macedonia (INNO-EEN 2014) (INNO-EEN 2014)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Coordination and support actions
Countries involved: North Macedonia
Call: INNOSUP (H2020-Adhoc-2014-20, 2014)
Start date: 2014-07-01
End date: 2014-12-31
Duration (months): 6.0
Total project cost (EUR): 3937.5
EU funding (EUR): 3150.0
Participants: 1
Project status: CLOSED

Through INNO-EEN 2014 project six 7-days service package services will be provided to four SMEs with significant innovation activities and high potential for internationalization and two SME instrument beneficiaries. As the national consortium is responsible for providing services at whole territory of the country, this project will also cover the same area. The services are delivered by two project experts/Key Account Managers (KAM) from UKIM, member of EEN Macedonia. In this way the project will be linked to EEN Macedonia. The activities within the project are organized in two work packages: key account management (KAM) for the beneficiaries of the SME instrument and enhancing SME innovation management capacity for innovating SME independently from a specific project. The selection of SMEs will be done based on identified criteria whereas services will be delivered in line with the specified common format with the packages. The team will use the IMP³rove tool as an assessment tool. The KAM will undertake gap assessment and needs/ identification activity and support the SMEs in selection of lead coach. It will then facilitate interactions between the SME, the lead coach and EC. The planned duration of the both work packages is six months (July – December 2014). The services, benefits and experiences from these activities will be part of the internal evaluation. The beneficiaries of these activities will be also used for identification of potential needs for trainings in the future.

Keywords: innovation,smes
Investigating embryonic development at the time of implantation using embryos and ES cells (embryonic rosettes)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2016-02-01
End date: 2018-01-31
Duration (months): 24.0
Total project cost (EUR): 183454.8
EU funding (EUR): 183454.8
Participants: 1
Project status: CLOSED

The mouse embryo is an excellent model for human development. Its preimplantation stages of development in vitro have been extensively studied. Now similar approaches can be applied to implantation stages, previously hidden from view in the uterus. It was recently revealed that formation of a rosette structure by pluripotent epiblast cells can be recapitulated by ES cells cultured in extracellular matrix proteins. I will determine the extent to which such rosettes can undertake autonomous development or if they require flanking extraembryonic tissues. I will characterise the patterns of the normal development of these tissues from the point of implantation to the time of gastrulation. I will determine the extent to which explants of extraembryonic tissues can influence the development of rosettes of epiblast cells. Altogether, these experiments will expand our knowledge of embryonic development and how to manipulate the developmental potential of pluripotent cells.

Keywords: mouse embryo,development,implantation,embryonic stem cells
ICT platform to reduce mortality rates for Transcatheter Aortic Valve Implantation (TAVI) by pre-operative risk management (TAVIguide)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: SME instrument
Countries involved: Belgium
Call: Open Disruptive Innovation Scheme (implemented through the SME instrument) (H2020-SMEINST-1-2015, 2015)
Start date: 2016-01-01
End date: 2016-04-30
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Our market disruptive TAVIguide™ ICT solution (a Software-as-a-Service platform) will be distinctly beneficial for the global healthcare system with a positive impact on two main groups: a favourable economic impact for medical centres and physicians and an improved quality of care and experience for patients. Our ICT platform addresses an innovative digital health ICT concept and service and will help to tackle the society's challenge of growing needs for sustainable and personalized healthcare (ICT Pillar VII “ICT-enabled benefits for EU society”). It provides surgeons with a groundbreaking ICT solution thanks to beyond State-of-the-Art patient-specific 3D heart modelling and blood flow simulation for pre-operative analysis and preparation of aortic valve implantation. These unique features, not found in competitive offerings, allow to correctly assess and mitigate the complications risk, thereby reducing mortality rates across all TAVI patients from up to 25% after 1 year to <5%. Our TAVIguide™ platform offers a huge potential to device manufacturers who can use the accurate modelling and simulation features to further optimize their TAVI devices and prepare the way for patient-specific valve design. Our business concept is based on a software license revenue model plus fee per case. FDA approval and validation in a prospective patient study during Phase 2 will give us a unique selling proposition for different TAVI stakeholders. Commercialization of TAVIguide™ is planned on a global scale (EU and US). Due to the growing medical importance of the TAVI procedure and an ageing population, the target TAVI market is expected to grow from 1.4B€ (2014) to 4.7B€ (2025). We aim for a 12.6% share by 2021. An additional market entry for mitral valve disease therapy, 4x the TAVI market size, will be analysed. The elaborated business plan and verified technical and marketing feasibility for additional medical applications will prepare our solution for fast market uptake.

Keywords: ict platform,3d simulation
Glucotanycytes: a role for hypothalamic barriers in the control of metabolism by peripheral glucose (GLUCOTANYCYTES)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: France
Call: Individual Fellowships (H2020-MSCA-IF-2016, 2016)
Start date: 2017-12-01
End date: 2019-11-30
Duration (months): 24.0
Total project cost (EUR): 173076.0
EU funding (EUR): 173076.0
Participants: 2
Project status: CLOSED

The escalating epidemic of obesity, type-2 diabetes and metabolic syndrome represents one of the most pressing and costly biomedical challenges confronting modern society. The impaired action of peripheral hormones on brain circuits controlling feeding and energy homeostasis, also known as "central hormone resistance", is increasingly recognized as playing a role in the pathophysiology of these disorders. The host laboratory has raised the groundbreaking notion that tanycytes, a specific type of hypothalamic glial cells, act as "gatekeepers" that regulate the access of blood-borne signals to the hypothalamus, and in particular, their vesicular transport into the cerebrospinal fluid, from where they enters other metabolic-hormone-sensitive regions. The overall objective of this proposal is to further develop this highly original angle by using state-of-the-art approaches to i) gain new insights into the molecular mechanisms underlying structural changes in the tanycytic barrier in response to fluctuating concentrations of circulating glucose, and determine how these processes are altered in animal models with acquired type-2 diabetes, and ii) explore the possibility that tanycytes are involved in the shuttling of circulating glucose into the cerebrospinal fluid (CSF) and that the tanycytic expression of the NMDA receptor plays a role in this process. This research promises to shed new light on the molecular mechanisms used by the hypothalamus to integrate key peripheral signals and coordinate energy homeostasis. The results will pave the way for the development of new treatment strategies to overcome hormone resistance in human obesity and associated metabolic syndromes.

Keywords: type 2 diabetes,obesity,glucose,tanycytes,blood brain barrier,plasticity,nmda,cerebrospinal fluid